Cargando…
Willingness to pay for a new drug delivery in Parkinson patients
OBJECTIVE: The Swedish reimbursement system operates a system where prices are set based on the expected value to the consumer. This value can be measured using willingness to pay (WTP). AIM: To assess Parkinson’s disease (PD) patients’ WTP for newly developed microtablets of levodopa in combination...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199841/ https://www.ncbi.nlm.nih.gov/pubmed/25336962 http://dx.doi.org/10.2147/JMDH.S67929 |
_version_ | 1782339984520380416 |
---|---|
author | Lökk, Johan Olofsson, Sara Persson, Ulf |
author_facet | Lökk, Johan Olofsson, Sara Persson, Ulf |
author_sort | Lökk, Johan |
collection | PubMed |
description | OBJECTIVE: The Swedish reimbursement system operates a system where prices are set based on the expected value to the consumer. This value can be measured using willingness to pay (WTP). AIM: To assess Parkinson’s disease (PD) patients’ WTP for newly developed microtablets of levodopa in combination with a drug-delivering electronic device (M/E) compared to standard treatment with levodopa in combination with the COMT (catechol-O-methyl transferase)-inhibitor entacapone (L/e). METHOD: A total of 2,000 randomly included PD patients had a postal questionnaire covering demographics, disease-specific issues, views on medication and WTP in different hypothetical scenarios. The first scenario was M/E with no change in effects or side effects; the second scenario was M/E with same effect and less side effects; and the third scenario was M/E with improved effect and less side effects. These scenarios were coupled to different costs to choose from. RESULTS: A total of 999 patients (50%) responded, mean age of 71 years and a mean PD duration of 9 years. Of all respondents, 50% preferred M/E before L/e in scenario one with increasing preference to scenario three. The average monthly WTP among all respondents in scenario one was SEK 230 and SEK 226 in L/e, both with an almost longitudinal doubling up to scenario three. Duration of PD-related symptoms, high education, and high medication intake implied a higher WTP in all scenarios in contrast to age, sex, and extra doses of levodopa. CONCLUSION: WTP for M/E increased gradually with high medication intake and education as well as with expected increased reduction of PD symptoms. |
format | Online Article Text |
id | pubmed-4199841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-41998412014-10-21 Willingness to pay for a new drug delivery in Parkinson patients Lökk, Johan Olofsson, Sara Persson, Ulf J Multidiscip Healthc Original Research OBJECTIVE: The Swedish reimbursement system operates a system where prices are set based on the expected value to the consumer. This value can be measured using willingness to pay (WTP). AIM: To assess Parkinson’s disease (PD) patients’ WTP for newly developed microtablets of levodopa in combination with a drug-delivering electronic device (M/E) compared to standard treatment with levodopa in combination with the COMT (catechol-O-methyl transferase)-inhibitor entacapone (L/e). METHOD: A total of 2,000 randomly included PD patients had a postal questionnaire covering demographics, disease-specific issues, views on medication and WTP in different hypothetical scenarios. The first scenario was M/E with no change in effects or side effects; the second scenario was M/E with same effect and less side effects; and the third scenario was M/E with improved effect and less side effects. These scenarios were coupled to different costs to choose from. RESULTS: A total of 999 patients (50%) responded, mean age of 71 years and a mean PD duration of 9 years. Of all respondents, 50% preferred M/E before L/e in scenario one with increasing preference to scenario three. The average monthly WTP among all respondents in scenario one was SEK 230 and SEK 226 in L/e, both with an almost longitudinal doubling up to scenario three. Duration of PD-related symptoms, high education, and high medication intake implied a higher WTP in all scenarios in contrast to age, sex, and extra doses of levodopa. CONCLUSION: WTP for M/E increased gradually with high medication intake and education as well as with expected increased reduction of PD symptoms. Dove Medical Press 2014-10-01 /pmc/articles/PMC4199841/ /pubmed/25336962 http://dx.doi.org/10.2147/JMDH.S67929 Text en © 2014 Lökk et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Lökk, Johan Olofsson, Sara Persson, Ulf Willingness to pay for a new drug delivery in Parkinson patients |
title | Willingness to pay for a new drug delivery in Parkinson patients |
title_full | Willingness to pay for a new drug delivery in Parkinson patients |
title_fullStr | Willingness to pay for a new drug delivery in Parkinson patients |
title_full_unstemmed | Willingness to pay for a new drug delivery in Parkinson patients |
title_short | Willingness to pay for a new drug delivery in Parkinson patients |
title_sort | willingness to pay for a new drug delivery in parkinson patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199841/ https://www.ncbi.nlm.nih.gov/pubmed/25336962 http://dx.doi.org/10.2147/JMDH.S67929 |
work_keys_str_mv | AT lokkjohan willingnesstopayforanewdrugdeliveryinparkinsonpatients AT olofssonsara willingnesstopayforanewdrugdeliveryinparkinsonpatients AT perssonulf willingnesstopayforanewdrugdeliveryinparkinsonpatients |